In January, ICO announced EyePrintPRO, a new corneal technology in the The Illinois Eye Institute. We are proud to introduce a second innovation in the clinic. It is called corneal cross-linking (CXL).
Cross-linking benefits patients with conditions like keratoconus or ectasia. Previously, the only solution for these issues was corneal implants, which come with a long recovery time and risk of rejection. Corneal cross-linking is non-invasive, using vitamin B2 (riboflavin) drops and UV light instead of surgery. Patients recover within days. “ICO is extremely excited,” says Dr. Jennifer Harthan. “This will serve as not only a treatment option for current patients, but future patients as well.”
Dr. Osvaldo Lopez, Chief of Ophthalmology at Advocate Illinois Masonic Medical Center, has been waiting for corneal cross-linking to come to the United States for over 15 years. When the FDA approved the Avedro system on April 18 of last year, he had ICO’s order placed within a week. “I find that ICO is a tremendous partner in this because of their reputation and the way they can reach out to the optometric community that no one else can,” he says.
Combined with EyePrintPRO, corneal cross-linking makes the Illinois Eye Institute a top-tier choice for corneal solutions. Says Dr. Leonard Messner, Executive Director, “The Illinois Eye Institute is delighted to offer this unique and transformative procedure.”
